Information Provided By: 
Fly News Breaks for May 10, 2019
FGEN
May 10, 2019 | 06:08 EDT
Piper Jaffray analyst Danielle Brill says she still has more questions than answers after FibroGen presented the MACE outcomes data with roxadustat. The analyst asks why there weren't any numbers provided and was there a pre-specified non-inferiority margin set with the FDA? She admits the statistical significant improvement on decline in kidney function is an encouraging finding, but says the "path forward is still very unclear to us." As such, Brill stays on the sidelines with a Neutral rating on FibroGen.
News For FGEN From the Last 2 Days
There are no results for your query FGEN
